Clinical Trials
14 trialsNCT01174121 2026-06-05
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03866382 2026-06-03
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03412877 2026-05-29
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT01408407 2026-05-14
Alkagin Paste in the Prevention of Radiation Dermatitis
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT04461509 2026-03-25
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT06353906 2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04624399 2025-11-18
ABACUS-2
Queen Mary University of London
Phase 2 Recruiting
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT04273061 2025-09-22
CAPTIV-8
British Columbia Cancer Agency
Phase 2 Recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06580002 2025-06-26
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
Phase 2 Recruiting